NDAINTRAVENOUSSOLUTION
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
IDAMYCIN PFS (idarubicin hydrochloride) by Pfizer is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 1997.
Drug data last refreshed 19h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDAMYCIN PFS is an intravenous anthracycline chemotherapy agent containing idarubicin hydrochloride approved in 1997. It inhibits DNA synthesis and topoisomerase II activity while generating DNA-damaging free radicals, making it a cytotoxic small molecule used in hematologic malignancies. The drug is administered as an IV solution and represents a mature oncology therapeutic with established clinical utility.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on market defense and cost management rather than growth initiatives.
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IDAMYCIN PFS offers stable, focused experience in mature oncology commercial execution and compliance management rather than innovation or launch experience. This role suits professionals seeking expertise in generic defense strategies, established product lifecycle management, and healthcare compliance in a commoditizing market.
Brand ManagerField Sales Representative
Worked on IDAMYCIN PFS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.